TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28698947

Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy at ‐110 °C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy at ‐60 °C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Local cryotherapy
Number of subjects: 60
Study: 25656426

Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 543

Group type: COMPARATOR
Intervention: Control (no xylitol)
Number of subjects: 543
Study: 23351036

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d,l-sotalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study: 21882343

Group type: EXPERIMENTAL
Intervention: in vivo silencing of miR-21 using a tiny seed-targeting LNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: treatment with anti-miR-21
Number of subjects: 0
Study: 19122476

Group type: EXPERIMENTAL
Intervention: HX575 (100 IU/kg body weight, subcutaneous, 3 times weekly for 4 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparator epoetin alfa (100 IU/kg body weight, subcutaneous, 3 times weekly for 4 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HX575
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparator epoetin alfa
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 80
Study: 17525168

Group type: EXPERIMENTAL
Intervention: Fosaprepitant 115 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fosaprepitant up to 150 mg (1 mg/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aprepitant 125 mg
Number of subjects: 0
Study: 16113431

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs) such as fluticasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs)
Number of subjects: 0
Study: 11165880

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 562

Group type: COMPARATOR
Intervention: Parenteral Nutrition (TPN)
Number of subjects: 562
Study: 9734729

Group type: EXPERIMENTAL
Intervention: Isolated soy protein containing moderate amounts of isoflavones (ISP56)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Isolated soy protein containing high amounts of isoflavones (ISP90)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (NCEP Step 1 diet with protein from casein and nonfat dry milk)
Number of subjects: 66
Study: 8036221

Group type: EXPERIMENTAL
Intervention: Multimodality treatment using oliphenum, prednisolone or their combination
Number of subjects: 60
Study: 31722404

Group type: EXPERIMENTAL
Intervention: rTMS (10 Hz, 1,500 stimuli)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 48
Study: 30594934

Group type: EXPERIMENTAL
Intervention: Low frequency stimulation (LFS) at 60 Hz and 80 Hz
Number of subjects: 15

Group type: COMPARATOR
Intervention: High frequency stimulation (HFS) at 110 Hz, 130 Hz, and 200 Hz
Number of subjects: 15
Study: 28843241

Group type: EXPERIMENTAL
Intervention: TPN with intravenous sodium glycerophosphate (Glycophos) 1.5 mmol/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: TPN without sodium glycerophosphate
Number of subjects: 0
Study: 25791025

Group type: EXPERIMENTAL
Intervention: Central site particle number concentration (PNC)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Near-highway and predicted residential PNC
Number of subjects: 2
Study: 23795788

Group type: EXPERIMENTAL
Intervention: Transurethral enucleation and resection of the prostate (TUERP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transvesical prostatectomy (TVP)
Number of subjects: 100
Study: 21129944

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 μg/nasal cavity twice daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 19001519

Group type: EXPERIMENTAL
Intervention: Individualized GH dose (17-100 microg/kg.d)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard GH dose (43 microg/kg.d)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Both GH-deficient and ISS groups
Number of subjects: 153
Study: 16730488

Group type: EXPERIMENTAL
Intervention: Valdecoxib, 40 mg, once a day for 5 days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 15380400

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 10904459

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 5 mg/d
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9265698

Group type: EXPERIMENTAL
Intervention: Pair-matched design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stratified designs
Number of subjects: 0
Study: 8319521

Group type: EXPERIMENTAL
Intervention: Intensified diet education
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 86
Study: 3521187

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Single-drug chemotherapy
Number of subjects: 128
Study: 28281940

Group type: EXPERIMENTAL
Intervention: Discrimination
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Racial identity
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Moderation of discrimination by racial identity
Number of subjects: 203
Study: 27400960

Group type: EXPERIMENTAL
Intervention: Pre-surgery physiotherapy intervention (2 times per week for 9 weeks) including specific exercises, motor control exercises, or traction, along with a tailor-made supervised exercise program.
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Pre-surgery physiotherapy intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: Waiting list group (control) receiving standardized information about surgery, post-surgical rehabilitation, and advice to stay active.
Number of subjects: 202
Study: 23722575

Group type: EXPERIMENTAL
Intervention: Fat reposition with pedicled infraorbital fat redraping (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Septal reset to reposition the underlying fat (Group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Septal reset (Group 2)
Number of subjects: 120
Study: 22829267

Group type: EXPERIMENTAL
Intervention: MSC (4 × 10(7) /injection) via intra-arterial and intravenous routes
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 20370417

Group type: EXPERIMENTAL
Intervention: Calcium sodium phosphosilicate dentifrice
Number of subjects: 110

Group type: COMPARATOR
Intervention: Potassium nitrate dentifrice
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 110
Study: 18206738

Group type: EXPERIMENTAL
Intervention: Defibrillator therapy
Number of subjects: 786

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 786

Group type: COMPARATOR
Intervention: No ICD therapy (control group)
Number of subjects: 786
Study: 15999885

Group type: EXPERIMENTAL
Intervention: Lidocaine gel (15 mL of 2% lidocaine administered intrarectally ten minutes before biopsy)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Lidocaine periprostatic infiltration (10 mL of 1% lidocaine given under ultrasound guidance in two periprostatic injections of 5 mL, four minutes before biopsy)
Number of subjects: 356
Study: 12450598

Group type: EXPERIMENTAL
Intervention: Combination therapy (half-dose reteplase and full-dose abciximab)
Number of subjects: 553

Group type: COMPARATOR
Intervention: Reteplase (standard-dose)
Number of subjects: 553
Study: 10363737

Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine 0.5% ophthalmic solution
Number of subjects: 176

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 176
Study: 7574130

Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Nebulized metaproterenol
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine and nebulized metaproterenol
Number of subjects: 154
Study: 2183055

Group type: EXPERIMENTAL
Intervention: 5-day course of continuous intravenous heparin with warfarin sodium begun on the first day
Number of subjects: 199

Group type: COMPARATOR
Intervention: 10-day course of intravenous heparin with warfarin sodium begun on the fifth day
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: 5-day course of continuous intravenous heparin
Number of subjects: 199

Group type: COMPARATOR
Intervention: 10-day course of intravenous heparin
Number of subjects: 199
Study: 6104634

Group type: EXPERIMENTAL
Intervention: GYKI-41099 2.5, 5 and 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Propranolol 10, 20 and 40 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GYKI-41099 5-15 mg daily for 2 months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GYKI-41099 in patients with mild hypertension
Number of subjects: 18
Study: 31851666

Group type: EXPERIMENTAL
Intervention: Integrative Medical Group Visits (IMGV)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Primary Care Provider (PCP) visit
Number of subjects: 159
Study: 30099412

Group type: EXPERIMENTAL
Intervention: Ginger supplementation (2g ginger powder for 10 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (2g wheat flour for 10 weeks)
Number of subjects: 45
Study: 26786921

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 825
Study: 25155980

Group type: EXPERIMENTAL
Intervention: Hand-held device with evidence-based software
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22040870

Group type: EXPERIMENTAL
Intervention: High-MUFA diet
Number of subjects: 466

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Habitual dietary PUFA:SFA ratio×PPARG Pro12Ala genotype interaction
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: PPARA Val162Leu×PPARG Pro12Ala genotype interaction
Number of subjects: 466
Study: 19169239

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 0.04 ml/1 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Photodynamic therapy plus intravitreal triamcinolone (PDT+IVTA) 0.1 ml/4 mg
Number of subjects: 28
Study: 17378845

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 788

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 788
Study: 15529514

Group type: EXPERIMENTAL
Intervention: Metformin-glibenclamide combination tablets (Glucovance)
Number of subjects: 477
Study: 11345366

Group type: EXPERIMENTAL
Intervention: Bradykinin (BK) administered at graded doses (0.2, 0.6, 2.0 microg/min) in ACE inhibitor group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Bradykinin (BK) administered at graded doses (0.2, 0.6, 2.0 microg/min) in non-ACE inhibitor group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Acetylcholine (ACh) (30 microg/min)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Papaverine (PA) (12 mg)
Number of subjects: 56
Study: 8989000

Group type: EXPERIMENTAL
Intervention: Small-dose hypobaric solution of 1% lidocaine 25 mg with fentanyl 25 micrograms
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional-dose hyperbaric solution of 5% lidocaine 75 mg
Number of subjects: 30
Study: 8085040

Group type: EXPERIMENTAL
Intervention: Passive motion rehabilitation with an automatic device (Toronto Mobilimb) for 2 hours per day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual rehabilitation program
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Passive motion rehabilitation with an automatic device (Toronto Mobilimb)
Number of subjects: 120
Study: 3315687

Group type: EXPERIMENTAL
Intervention: Theophylline preparation (18 mg/kg per day at 2000 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31758401

Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31197364

Group type: EXPERIMENTAL
Intervention: Fluoride varnish containing 1.5% ammonium fluoride applied every sixth week during orthodontic treatment.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo varnish without fluoride applied every sixth week during orthodontic treatment.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo group (Control)
Number of subjects: 182
Study: 28463940

Group type: EXPERIMENTAL
Intervention: SGS 2.5%
Number of subjects: 76

Group type: COMPARATOR
Intervention: NS
Number of subjects: 76
Study: 26828596

Group type: EXPERIMENTAL
Intervention: Endoscopic stone extraction (ERCP) followed by laparoscopic cholecystectomy (LC) and intraoperative cholangiogram (IOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study: 24166941

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non‐specific neurocognitive therapy (NNT)
Number of subjects: 40
Study: 23163144

Group type: EXPERIMENTAL
Intervention: Restitution combined with percutaneous vertebroplasty (PVP)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Restitution combined with PVP
Number of subjects: 132
Study: 19827964

Group type: EXPERIMENTAL
Intervention: Topical morphine solution (2 per thousand)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 9
Study: 17440161

Group type: EXPERIMENTAL
Intervention: PELFw regimen (8 weekly administrations of cisplatin 40 mg/m2, LV 250 mg/m2, epidoxorubicin 35 mg/m2, 5-FU 500 mg/m2, glutathione 1.5 g/m2 with filgrastim)
Number of subjects: 400

Group type: COMPARATOR
Intervention: 5-FU/LV regimen (6 monthly administrations of a 5-day course of 5-FU 375 mg/m2 daily and LV 20 mg/m2 daily)
Number of subjects: 400
Study: 16125523

Group type: EXPERIMENTAL
Intervention: Carnitine supplementation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dietary modifications and increased physical activity
Number of subjects: 70
Study: 12123399

Group type: EXPERIMENTAL
Intervention: 1000 mg/d ER niacin
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: 1500 mg/d ER niacin
Number of subjects: 148
Study: 10354968

Group type: EXPERIMENTAL
Intervention: Indinavir (800 mg every 8 hours from days 2 to 7)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9420871

Group type: COMPARATOR
Intervention: Micronized estradiol (n = 8)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Micronized progesterone (n = 8)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Combination of micronized estradiol and progesterone (n = 7)
Number of subjects: 23
Study: 2048454

Group type: EXPERIMENTAL
Intervention: Brand-switching procedure
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Three-stage set of 'Nicotine Faders' graduated filters
Number of subjects: 110

Group type: COMPARATOR
Intervention: Both methods (Brand-switching and Nicotine Faders)
Number of subjects: 110
Study: 7316248

Group type: EXPERIMENTAL
Intervention: Rush Immunotherapy (IT) with four Ag dilutions: 10, 100, 1000, and 5000 pnu/ml, maintenance dose of 0.5 ml of the 5000 pnu/ml solution achieved in 7 to 18 weeks (mean 12 weeks).
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group: Five patients who had repeat BPTs to the same Ag without IT.
Number of subjects: 13
Study: 30993855

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 units/mL (Gla-300)
Number of subjects: 638

Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL (Gla-100)
Number of subjects: 638
Study: 28256054

Group type: EXPERIMENTAL
Intervention: Lixisenatide (LIXI)
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1198
Study: 25683938

Group type: EXPERIMENTAL
Intervention: Sorafenib combined with RFA (n=30)
Number of subjects: 62

Group type: COMPARATOR
Intervention: RFA alone (n=32)
Number of subjects: 62
Study: 24644241

Group type: EXPERIMENTAL
Intervention: high-fat/exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: high-fat/sedentary
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: low-fat/exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: low-fat/sedentary
Number of subjects: 6
Study: 22644173

Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 18
Study: 20012810

Group type: EXPERIMENTAL
Intervention: TAAG intervention
Number of subjects: 0
Study: 17317857

Group type: EXPERIMENTAL
Intervention: Dasatinib (140 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: High-dose imatinib (800 mg)
Number of subjects: 150
Study: 15345173

Group type: EXPERIMENTAL
Intervention: Laser therapy (He-Ne laser applied to three trigger points in the upper trapezius muscles with 632.8 nm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dry needling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 60
Study: 11274941

Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization (TLR)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control
Number of subjects: 188
Study: 9893457

Group type: EXPERIMENTAL
Intervention: 8-week prednisolone + 2-year Sairei-to
Number of subjects: 196

Group type: COMPARATOR
Intervention: 18-week prednisolone + 2-year Sairei-to
Number of subjects: 196
Study: 8276650

Group type: EXPERIMENTAL
Intervention: Early locoregional radiotherapy (40 Gy in 15 fractions in 3 weeks)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Late locoregional radiotherapy (40 Gy in 15 fractions in 3 weeks)
Number of subjects: 308
Study: 3885672

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Pethidine 50 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 31186177

Group type: EXPERIMENTAL
Intervention: Automated Bone Scan Index (aBSI) increase during treatment
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (aBSI change >0.3)
Number of subjects: 176
Study: 29913318

Group type: EXPERIMENTAL
Intervention: Family Wellbeing interventions
Number of subjects: 0
Study: 27564283

Group type: EXPERIMENTAL
Intervention: Doxazosin Oral Intake Therapy (4 mg once daily for 4 weeks)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Doxazosin Oral Intake Therapy
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 24169147

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 10 mg PO twice daily for six weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 60
Study: 22429179

Group type: EXPERIMENTAL
Intervention: Video-based cases
Number of subjects: 5224

Group type: COMPARATOR
Intervention: Text-based cases
Number of subjects: 5224
Study: 20407232

Group type: EXPERIMENTAL
Intervention: Late GH therapy (0.46 mg/kg/week)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Early GH therapy (0.46 mg/kg/week)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No GH therapy (Control)
Number of subjects: 58
Study: 18039957

Group type: EXPERIMENTAL
Intervention: Increased intensity postinduction intensification (PII)
Number of subjects: 2078

Group type: COMPARATOR
Intervention: Standard duration postinduction intensification (PII)
Number of subjects: 2078

Group type: COMPARATOR
Intervention: Longer duration postinduction intensification (PII)
Number of subjects: 2078
Study: 17886000

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15159317

Group type: EXPERIMENTAL
Intervention: Reduction group (smokers reducing CPD by 25% to 75%)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Waitlist group (baseline measurements before joining reduction group)
Number of subjects: 151
Study: 11432176

Group type: EXPERIMENTAL
Intervention: Preemptive multimodal analgesia (diclofenac, butorphanol, and lidocaine)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no preemptive multimodal analgesia)
Number of subjects: 82
Study: 9183129

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) titrated to a target dose of 0.7 mg/kg twice a day
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 1537636

Group type: EXPERIMENTAL
Intervention: Family therapy intervention
Number of subjects: 0
Study: 3895761

Group type: EXPERIMENTAL
Intervention: Bepridil 200 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bepridil 400 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bepridil 600 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30679315

Group type: COMPARATOR
Intervention: Gemcitabine 1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle with erlotinib 100 mg p.o. daily (Arm A)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle with erlotinib 100 mg p.o. daily and panitumumab 4 mg/kg on days 1 and 15 of a 28-day cycle (Arm B)
Number of subjects: 92
Study: 28635375

Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy
Number of subjects: 0
Study: 26763949

Group type: EXPERIMENTAL
Intervention: 19-week (3 times/wk) progressive mixed (aerobic/strength/balance/flexibility) community group exercise program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matched duration home stretching program
Number of subjects: 40
Study: 24659622

Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 8
Study: 21470787

Group type: EXPERIMENTAL
Intervention: High-dose external-beam radiation therapy (EBRT) (79.2 Gray equivalent using photons and protons)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Permanent prostate brachytherapy
Number of subjects: 282
Study: 19865063

Group type: EXPERIMENTAL
Intervention: Alprazolam 1.5 mg daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17495708

Group type: EXPERIMENTAL
Intervention: Brief personalized motivational intervention (PMI)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Brief information and advice (BIA)
Number of subjects: 497
Study: 15517143

Group type: EXPERIMENTAL
Intervention: C-TRUS
Number of subjects: 132
Study: 11548897

Group type: EXPERIMENTAL
Intervention: 120 mg Ginkgo biloba extract EGb 761 twice daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: 12 mg Ginkgo biloba extract EGb 761 twice daily
Number of subjects: 106